Last reviewed · How we verify
NCT05852171: B-IGM
Baricitinib in Idiopathic Granulomatous Mastitis
Phase 2 trial testing Baricitinib in Mastitis Chronic in 20 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2025
Quick facts
| Lead sponsor | First Affiliated Hospital of Zhejiang University |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 4 May 2023 |
| Primary completion | 30 April 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Baricitinib (baricitinib) — full drug profile →
Conditions studied
- Mastitis Chronic — all drugs for Mastitis Chronic →
- Idiopathic Granulomatous Mastitis — all drugs for Idiopathic Granulomatous Mastitis →
Sponsor
First Affiliated Hospital of Zhejiang University
Who can join
Adults 18 to 70, female only, with Mastitis Chronic or Idiopathic Granulomatous Mastitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will explore the mechanism of targeted drug in treatment of idiopathic granulomatous mastitis, and clarify the clinical classification and corresponding markers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05852171
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Baricitinib
Trials testing the same drug.
- NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
- NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07268534 — Biologics in Folliculitis Decalvans : an Adaptative Trial Research · Phase 2 · not yet recruiting
- NCT06923072 — Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement · Phase 2 · recruiting
Other recruiting trials for Mastitis Chronic
Currently open trials in the same condition.
- NCT06665399 — Observation Alone for Mild Non-Lactational Mastitis · recruiting
- NCT06667609 — Validity and Reliability of the Mastitis Symptom Severity Assessment Methods (M-Score and BISSI) in Non-Lactational Mast · active not recruiting
Other First Affiliated Hospital of Zhejiang University trials
Trials by the same sponsor.
- NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
- NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
- NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05852171 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
- Last refreshed: 14 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05852171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing